FORMAT FOR SUBMISSION OF PROTOCOL INVOLVING RESEARCH IN HUMAN SUBJECTS FOR CLEARANCE BY INSTITUTE ETHICS COMMITTEE OF AIIMS FOR DM / M.Ch/ MD / MS / MHA / MDS /M.Sc / M.Biotech./MBBS AND Ph.D. STUDENTS (FOR THESIS OR DISSERTATION)

Submit fifteen (15) copies of the Research Project along with Covering letter and 'soft copy' on CD with following information to the Member Secretary, Institute Ethics Sub-Committee at Room No. 102, 1st Floor, Old OT Block, AIIMS, Tel No.**4579.** The Investigator must submit protocol through Chief Guide and Head of Department who ensures that the project has been wetted both from the scientific and ethical point of view.

No research project shall be / can be started unless ethics clearance/approval is obtained. Please bear in mind that no retrospective / post facto ethical clearance can be provided to research projects which were neither submitted nor wetted by the ethics committee.

All submissions should be made in the prescribed Format of the **Institute Ethics Sub-Committee** with signatures of all the investigators. The submission must be accompanied with *Participant Informed Consent Form* (PICF) and *Participant Information Sheet* (PIS), both in English and Hindi, in a simple layman's language in a narrative form, directed to Participant /LAR, covering all the points given on the website. (See AIIMS website at www.aiims.ac or www.aiims.edu in for details / proforma). Also ensure that all the pages are numbered.

Project Submission Time: Submissions will be received on all days. Proposals received till 15th of any month will be processed in the coming Institute Ethics Committee and Institute Ethics Sub-Committee meetings and those received after 15th will be processed in the next Institute Ethics Committee and Institute Sub-Committee meetings. All meetings of Institute Ethics Committee will be held on first Monday as far as possible of Jan, Feb, March, April, May, June, July, August, September, October, November, December and those of Institute Ethics Sub-Committee on the immediately preceding Friday of the above dates.

While submitting replies raised by the Institute Ethics Committee/Sub-Committee, the candidates are advised to mention the Institute Ethics Committee/Sub-Committee reference number/s and also attach a copy of the comments of the Institute Ethic Committee/Sub-Committee.

It is desirable that topics pertaining to clinical/drug trials should be avoided as thesis topics to Ph.D / DM / M.Ch / MD / MS / MHA / MDS / M.Sc. / M.Biotech and MBBS students. In case these are given, appropriate DCGI permission should be available.

Reply Submission: While submitting reply raised by the Ethics Committee/Sub-Committee, the Investigators are advised to submit these through Chief-Guide. They should also mention the Ethics Committee/Sub-Committee Reference number/s and also attach a copy of the comments of the Ethic Committee/Sub-Committee. These changes should be incorporated as a soft copy in the CD.

Amendment Submission: While submitting amendments in protocols a covering letter should be provided clearly stating the changes and soft copy of the same should be submitted in a CD.

The research projects proposal submitted should be as follows:

1. Full Title of Study:	
1a. AIIMS Temporary Research Section Number for all Clinical Trials which are privately funded	
2.1 Name & signatures of the candidate	2.1Signatures
2.2 Department	2.2
2.3 Degree/course	2.3 B.Sc/MBBS/M.Sc/MD/MS/MHA/MDS/M.Biotech/MCh/DM/ Ph.D (encircle)
2.4 Batch of admission to course	2.4 January/July (year)
2.5 Month & year of submission of thesis	2.5 June/November(year)
2.6 Email ID of the Candidate and Chief Guide.	
3. Name of Faculty & Department (Guide/Co-guide) (Minimum two co-guides signatures are required)	Signatures (Guide/Co-Guides)
3.1	3.1
3.2	3.2
3.3	3.3
3.4	3.4
3.5(Expand if any more co-guides)	3.5
4. Objectives of the study	4.1
	4.2
	4.3
	4.4
	4.5
5. Why this study is required? Please provide brief justification.	
6. Methodology	6.1. Number of Patients:

	6.2. Inclusion criteria
	a)
	b)
	c)
	d)
	6.3. Exclusion criteria
	a)
	b)
	c)
	d)
	6.4. Control(s)
	6.5. Study design
	6.6. Dosages of drug
	6.7. Duration of treatment
	6.8. Investigation specifically related to projects
	6.9 Permission to use copyrighted Questionnaire/profroma
	6.9. Others
	6.10 Brief Methodology
7. Permission from Drug Controller	1. ☐ Required 2. ☐ Not required
General of India (DCGI)	3. Received 4. Applied when:
· ,	
8. Permission from DGFT, if required	1. ☐ Required 2. ☐ Not required
•	3. Received 4. Applied when:
9. a) Safety measures for proposed	a)
interventions	
b) Results of relevant laboratory tests	b)
c) Result of studies in human	,
,	c)
10. Plans to withdraw standard therapy	, — — — — — — — — — — — — — — — — — — —
in research	☐ Yes ☐ No
	_
	Remarks:
11. Plan for provision of coverage for	
medical risk	
12. How you will maintain	
Confidentiality of subject?	
, ,	
13. Costs Involved (Appx. in Rs.)	
13.1 Investigations	13.1
13.2 Disposables	13.2
13.3 Implants	13.3
13.4 Drugs / Contrast Media	13.4
Who will bear the costs of the	1. Patient 2. Project 3. Exempted
requirements? $(mark \ \lor)$	4. Other Agencies (Name)
14. Participant Information Sheet	Attached English version
(mark $\sqrt{if yes}$)	Attached Hindi versiom
	Certified that Hindi version is a true translation of English version

15. Participant Informed Consent Form	Attached English version
$(mark \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$	Attached Hindi versiom
	Certified that Hindi version is a true translation of English version
16. Whether any work on this project	\square (mark \sqrt{if} yes, X if no)
has started or not?	(Please enclose a separate certificate to this effect).
17.Attached documents	17.1 Covering letter, through proper channel.
(If any)	17.2 Copy of the detailed protocol is mandatory
	17.3 Undertaking that the study shall be done in accordance
	with ICMR and GCP guidelines
	17.4 In case of multicentric study, IEC clearance of other
	centers must be provided
	17.5 Definite undertaking as to who will bear the
	expenditure of injury related to the project
	17.6 In case an insurance cover is intended, Insurance
	certificate must be provided (as per ICMR guidelines)
	17.7 : Permission as mentioned in 6.9
	17.8: Certificate/undertaking as mentioned in 16
	17.9 In case of Clinical trials, proof of registration of
	Clinical trial with ICMR needs to be submitted.
	17.10 Investigator should provide undertaking what they
	will do with the leftover sample tissue
	17.11 Soft Copy on CD:
	17.12 Others: